Baseline history of patients using selexipag for pulmonary arterial hypertension

INTRODUCTION: Since its introduction to the market in 2016, selexipag has been an alternative oral therapy among both treatment-naïve patients and those with mono or dual therapy failure; however, limited information is available regarding the presentation and management of patients with pulmonary a...

Descripción completa

Detalles Bibliográficos
Autores principales: Highland, Kristin B., Hull, Michael, Pruett, Janis, Elliott, Caitlin, Tsang, Yuen, Drake, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466463/
https://www.ncbi.nlm.nih.gov/pubmed/30983530
http://dx.doi.org/10.1177/1753466619843774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6466463/
https://www.ncbi.nlm.nih.gov/pubmed/30983530
http://dx.doi.org/10.1177/1753466619843774

Ejemplares similares